NCT05378425 - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

CancerTumor, SolidAdvanced Solid TumorMetastatic CancerLocally Advanced Solid Tumor

Interventions

DRUG

NTX-1088

IgG4 mAb targeting the poliovirus receptor (PVR, CD155).

DRUG

Pembrolizumab

IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

Trial Locations (6)

70121

RECRUITING

Ochsner Clinic Foundation, New Orleans

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

5262131

RECRUITING

Sheba Medical Center, Ramat Gan

9574425

RECRUITING

Hadassah Medical Center, Jerusalem

Unknown

NOT_YET_RECRUITING

Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw